Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Fang, Xiaosheng ^a   Zhou, Xiangxiang ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clinical development; NHL; PI3K inhibitors

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO [':4, 5] FURO [3, 2 D] PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; BUPARLISIB; COPANLISIB; DACTOLISIB; DUVELISIB; EVEROLIMUS; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN TYROSINE KINASE; RHEB PROTEIN; RITUXIMAB; S6 KINASE; TUBERIN; TUMOR SUPPRESSOR PHOSPHATASE AND TENSIN HOMOLOG; UNCLASSIFIED DRUG;

BURKITT LYMPHOMA; CELL GROWTH; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; METABOLIC ACTIVATION; NEOPLASM; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

EID: 84992373341     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-30     Document Type: Review

References (64)

1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012, 149:274-293. 10.1016/j.cell.2012.03.017, 3331679, 22500797.
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187. 10.1056/NEJMra044389, 16014887.
3. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010, 7:367-380. 10.1038/nrclinonc.2010.84, 20551944.
4. Fang X, Jiang Y, Feng L, Chen H, Zhen C, Ding M, Wang X. Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70. Cancer Cell Int 2013, 13:48. 10.1186/1475-2867-13-48, 3680239, 23706027.
5. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 2009, 9:550-559. 10.2174/187152009788451851, 19519296.
6. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510. 10.1038/onc.2008.245, 3398461, 18794884.
7. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083. 10.1200/JCO.2009.25.3641, 2834432, 20085938.
8. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148, 15718470.
10. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464. 10.1038/sj.onc.1209085, 16288292.
11. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644. 10.1038/nrd2926, 3142564, 19644473.
12. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005, 102:802-807. 10.1073/pnas.0408864102, 545580, 15647370.
13. Clinical Trials.gov. http://www.clinicaltrials.gov/.
14. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010, 24:1781-1784. 10.1038/leu.2010.154, 3027218, 20703254.
15. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107. 10.1158/0008-5472.CAN-10-1814, 20876803.
16. Zang C, Eucker J, Liu H, Muller A, Possinger K, Scholz CW. Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett 2013, 339:288-297. 10.1016/j.canlet.2012.11.013, 23200668.
17. Civallero M, Cosenza M, Marcheselli L, Pozzi S, Sacchi S. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opin Investig Drugs 2012, 21:1597-1606. 10.1517/13543784.2012.719871, 22920938.
18. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116:2078-2088. 10.1182/blood-2010-02-271171, 2951855, 20522708.
19. Kahl B, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM, Furman RR, Brown JR, Coutre S, Lannutti B, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2010, 116:1777.
20. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 2013, 133:247-252. 10.1002/ijc.27989, 23238639.
21. Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW. Inhibition of pan-class I PI3 kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B cell lymphoma. Leuk Lymphoma in press. Epub 2013 Jul 25.
22. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186. 10.1182/blood-2006-04-016907, 16946303.
23. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D, Harhalakis N, Pappa V, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009, 15:5724-5732. 10.1158/1078-0432.CCR-08-3215, 19723646.
24. Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22:167-179. 10.1016/j.ccr.2012.06.012, 3432451, 22897848.
25. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009, 69:3520-3528. 10.1158/0008-5472.CAN-08-4884, 19351820.
26. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S, Auer R, Gribben J, Joel S. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013, 121:2274-2284. 10.1182/blood-2012-10-460832, 23341541.
27. Martin-Sanchez E, Rodriguez-Pinilla SM, Sanchez-Beato M, Lombardia L, Dominguez-Gonzalez B, Romero D, Odqvist L, Garcia-Sanz P, Wozniak MB, Kurz G, et al. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica 2013, 98:57-64. 10.3324/haematol.2012.068510, 3533660, 22801959.
28. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21:333-339. 10.1038/sj.leu.2404471, 17136116.
29. Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol Cancer Res 2012, 10:347-359. 10.1158/1541-7786.MCR-11-0394, 3378513, 22241218.
30. Gulmann C, Espina V, Petricoin E, Longo DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005, 11:5847-5855. 10.1158/1078-0432.CCR-05-0637, 16115925.
31. Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournie JJ, Laurent G, Bezombes C. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012, 26:795-805. 10.1038/leu.2011.248, 21926965.
32. Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer 2013, 133:984-996. 10.1002/ijc.28073, 23475782.
33. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer 2013, 133:505-513. 10.1002/ijc.28034, 23319394.
34. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002, 94:1204-1210. 10.1093/jnci/94.16.1204, 12189223.
35. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815. 10.1056/NEJMra041720, 15728813.
36. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012, 5:55. 10.1186/1756-8722-5-55, 3465197, 22980425.
37. Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 2010, 3:33. 10.1186/1756-8722-3-33, 2954871, 20843302.
38. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002, 100:3741-3748. 10.1182/blood-2002-02-0539, 12393602.
39. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594. 10.1182/blood-2010-03-275305, 3694505, 20959606.
40. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612. 10.1182/blood-2011-05-352492, 21803855.
41. Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SEF, Lannutti BJ, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Meeting Abstracts 2011, 29:6631.
42. Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. ASCO Meeting Abstracts 2011, 29:3064.
43. Rosich L, Saborit-Villarroya I, Lopez-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, Villamor N, Campo E, Perez-Galan P, Roue G, Colomer D. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013, 98:1739-1747. 10.3324/haematol.2013.088849, 3815175, 23850807.
44. Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol 2013, 92:1351-1358. 10.1007/s00277-013-1770-9, 23636313.
45. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032. 10.1182/blood-2011-01-293050, 3109529, 21300984.
46. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, Soderberg O, Enblad G, Rosen A, Mustelin T, Jerkeman M, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma 2007, 48:2221-2232. 10.1080/10428190701636443, 17926183.
47. Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, Dorken B, Lenz P, Lenz G, Krappmann D. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2011, 108:272-277. 10.1073/pnas.1008969108, 3017191, 21173233.
48. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012, 30:282-290. 10.1200/JCO.2011.36.1360, 22162589.
49. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
50. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38. 10.1182/blood-2010-04-189977, 3037747, 20940415.
51. Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol 2011, 48:214-226. 10.1053/j.seminhematol.2011.05.001, 3143377, 21782064.
52. Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 2005, 105:3722-3730. 10.1182/blood-2004-10-3999, 1895014, 15650054.
53. Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK, Zago MA. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005, 130:516-526. 10.1111/j.1365-2141.2005.05630.x, 16098065.
54. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4:117-126. 10.1038/nrm1018, 12563289.
55. Muller A, Zang C, Chumduri C, Dorken B, Daniel PT, Scholz CW. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer 2013, 133:1813-1824. 10.1002/ijc.28206, 23580240.
56. Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk Res 2012, 36:912-920. 10.1016/j.leukres.2012.02.010, 22560334.
57. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009-3020. 10.1182/blood-2004-02-0405, 15265787.
58. Jiang Y, Wang X. Comparative mitochondrial proteomics: perspective in human diseases. J Hematol Oncol 2012, 5:11. 10.1186/1756-8722-5-11, 3337254, 22424240.
59. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, Kutok JL, Kearney JF, Otipoby KL, Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586. 10.1016/j.cell.2009.08.041, 2787092, 19879843.
60. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013, 121:2964-2974. 10.1182/blood-2012-08-446096, 3624942, 23403624.
61. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26:6184-6193. 10.1038/sj.onc.1210448, 17420722.
62. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650. 10.1182/blood-2009-02-206722, 2713461, 19458356.
63. Borlado LR, Redondo C, Alvarez B, Jimenez C, Criado LM, Flores J, Marcos MA, Martinez AC, Balomenos D, Carrera AC. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. Faseb J 2000, 14:895-903.
64. Uner AH, Saglam A, Han U, Hayran M, Sungur A, Ruacan S. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leuk Lymphoma 2005, 46:1463-1470. 10.1080/10428190500144813, 16194892.